Patent ID: 7781473

Claim:
A method of treating benign prostatic hyperplasia (BPH), comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) is W is selected from the group consisting of O, S and NR F ; wherein R F is selected from the group consisting of hydrogen, hydroxy, C 1-4 alkyl, C 1-4 alkoxy, cyano and —SO 2 —C 1-4 alkyl; R l is selected from the group consisting of C 1-4 alkyl and halogenated C 1-4 alkyl; R 2 is selected from the group consisting of hydrogen, C 1-4 alkyl, halogenated C 1-4 alkyl, —C(O)O—C 1-4 alkyl, —C(O)—C 1-4 alkyl and —C(O)-(halogenated C 1-4 alkyl); a is an integer from 0 to 1; R 3 is selected from the group consisting of hydrogen, halogen, C 1-4 alkyl, halogenated C 1-4 alkyl, cyano, nitro, amino, benzyl, —O-phenyl, —C(O)-phenyl, —S(O) 0-2 —C 1-4 alkyl, C 1-4 alkylamino, di C 1-4 alkylamino, —O—C 1-4 alkyl, —NR A —C(O)—C 1-4 alkyl and —S(O) 0-2 -phenyl, wherein R A is either hydrogen or C 1-4 alkyl; R 4 is selected from the group consisting of hydrogen, halogen, C 1-4 alkyl, halogenated C 1-4 alkyl, cyano, nitro, amino, benzyl, —O-phenyl, —C(O)-phenyl, —S(O) 0-2 —C 1-4 alkyl, C 1-4 alkylamino, di C 1-4 alkylamino, —O—C 1-4 alkyl, —NR B —C(O)—C 1-4 alkyl and —S(O) 0-2 -phenyl, wherein R B is either hydrogen or C 1-4 alkyl; provided that at least one of R 3 or R 4 is other than hydrogen; R 6 and R 7 are each independently selected from the group consisting of hydrogen, halogen, C 1-4 alkyl, C 2-4 alkenyl, C 1-4 alkoxy, cyano, —C(O)O—C 1-4 alkyl and —S(O) 0-2—C 1-4 alkyl; is selected from the group consisting of wherein R 5′ is selected from the group consisting of halogen and C 1-4 alkyl; and wherein R 10 is selected from hydrogen, C 1-4 alkyl, benzyl or —C(O)—CF 3 ; R 5 is selected from the group consisting of hydrogen, carboxy, alkyl, halogenated C 1-4 alkyl, hydroxy substituted C 1-4 alkyl, cycloalkyl, aryl, aralkyl, —C(O)—C 1-4 alkyl, —C(O) -(halogenated C 1-4 alkyl), —C(O)O—C 1-4 alkyl, —C(O)O-aryl, —C 1-4 alkyl-S(O) 0-2 —C 1-4 alkyl, t-butyl-dimethyl-silyl and trimethylsilyl; wherein the aryl, whether alone or as part of a substituent group is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, C 1-4 alkyl, C 1-4 alkoxy, halogenated C 1-4 alkyl, cyano, nitro, —NR C —C(O)—C 1-4 alkyl, NR C —C(O)-(halogenated C 1-4 alkyl), —C(O)O—C 1-4 alkyl, trimethyl-silyl and t-butyl-dimethyl-silyloxy; wherein R C and R D are each independently selected from hydrogen or C 1-4 alkyl; or a pharmaceutically acceptable salt thereof.